Amarin told the market the US Food and Drug Administration’s office of new drugs had denied its appeal of the decision to withdraw approval of its Anchor clinical trial, designed to expand its market for Vascepa by including patients with lower but still elevated levels of blood fats.

Shares in Irish pharmaceuticals group Amarin slumped more than 20 per cent yesterday as the US regulator shut the door on the company’s plans to exten(...)

John Thero, Amarin chief executive. Photograph: Cyril Byrne / The Irish Times

Amarin has today asked a federal court to order the US Food and Drug Administration to give the company’s Vascepa fish oil pill five years of (...)

Advisers to the Food and Drug Administration had in October recommended that the agency not approve Vascepa for the new use until the larger 8,000-patient trial shows that lowering blood fats leads to reduced cardiovascular risk. The Irish drugmaker said it planned to appeal the decision.

Shares in Irish drugmaker Amarin haver fallen almost 30 per cent in two days after US health regulators rejected a preset testing process that was cri(...)

 Aer Lingus has added Pula to its destinations, bringing the Istrian peninsula and pretty towns such as Porec within easy reach for short breaks and holidays
Ask Joan

We have travelled to Dubrovnik and surrounding Islands for the last seven years. We love it but find it getting increasingly more expensive. I see Aer(...)

Amarin chief executive Joseph Zakrzewski said the company had reduced staff levels by half as announced in the aftermath of its failure to secure support from a Food and Drug Administration (FDA) advisory panel for its proposal to expand its target market. Photograph: Cyril Byrne /The Irish Times

Future prospects for Irish biopharma group Amarin are uncertain after it raised doubts last night about its ability to fund a key trial to extend the (...)

For your diary

TODAYResults: Ryanair; PostNL.Indicators: Irish exchequer returns (Jan-Oct); German Markit manufacturing PMI (Oct); Euro zone Markit manufacturing PMI(...)

It may not quite be throwing in the towel, but Irish biopharma Amarin is definitely taking a step back after its calamitous loss before an FDA advisory panel.

It may not quite be throwing in the towel, but Irish biopharma Amarin is definitely taking a step back after its calamitous loss before an FDA advisor(...)

Shares in Irish drug company Amarin slumped as much as 64 per cent on Thursday, a day after an advisory committee to the US Food and Drug Administrati(...)

Vascepa, the fish-oil pill developed by Irish drug company Amarin last night failed to win the backing of US advisers to significantly expand its use (...)

Amarin investors are getting decidedly twitchy. And with good reason. The Irish company this week goes before a US Food and Drug Administration panel (...)